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Abstract  
Background: A meta-analysis of the effects of HER2 status, specifically within the first 2-3 years of adjuvant 
endocrine therapy, has the potential to inform patient selection for upfront AI therapy or switching strategy 
tamoxifen followed by AI. The pre-existing standardization of methodology for HER2 (IHC/FISH) facilitates 
analysis of existing data for this key marker. 
Methods: Following a prospectively designed statistical analysis plan, patient data from 3 phase III trials 
(ATAC, BIG-1-98 and TEAM) comparing an AI to tamoxifen during the first 2-3 years of adjuvant endocrine 
treatment were collected and a treatment-by-marker analysis of distant recurrence-free interval–censored at 2-3 
years treatment–for HER2 status x AIvsTam treatment was performed to address the clinical question relating 
to efficacy of “upfront” versus “switch” strategies for AIs. 
Results: A prospectively planned, patient-level data meta-analysis across 3 trials demonstrated a significant 
treatment (AIvsTam) by marker (HER2) interaction in a multivariate analysis; (interaction HR=1.61, 95%CI 
1.01-2.57; p<0.05). Heterogeneity between trials did not reach statistical significance. The HER2-ve group 
gained greater benefit from AI versus Tam (HR=0.70, 95%CI 0.56-0.87) than the HER2+ve group (HR=1.13, 
95%CI 0.75-1.71). However, the small number of HER2+ve cases (n=1092 across the 3 trials) and distant 
recurrences (n=111) may explain heterogeneity between trials. 
Conclusions: A patient level data meta-analysis demonstrated a significant interaction between HER2 status 
and treatment with AIvsTam in the first 2-3 years of adjuvant endocrine therapy. Patients with HER2-ve 
cancers experienced improved outcomes (distant relapse) when treated with upfront AI rather than tamoxifen, 
whilst patients with HER2+ve cancers fared no better or slightly worse in the first 2-3 years. However, the small 
number of HER2+ve cancers/events may explain a large degree of heterogeneity in the HER2+ve groups across 
all 3 trials. Other causes, perhaps related to subtle differences between AIs, cannot be excluded and warrant 
further exploration. 
Keywords 
Breast cancer, HER2, prediction, aromatase inhibitor, meta-analysis 
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Introduction  
For well over 20 years the HER2 (neu/c-erb-b2) oncogene has been associated with resistance to endocrine 
therapy [1]. As knowledge relating to extended type I receptor tyrosine kinase family (RTK; EGFr, HER2, 
HER3 and HER4) signaling was developed, functional and clinical evidence substantiating the link between 
resistance to tamoxifen therapy and type I RTK expression became more extensive [1-3]. A decade ago we 
suggested that analysis of type I RTKs might be of value in determining which patients were most likely to 
benefit from aromatase inhibitor (AI) rather than tamoxifen therapy [4]. At this time we made two critical 
observations relevant for the clinical setting, firstly, that the impact of HER2 and other type I RTK status on 
outcome following tamoxifen therapy was time dependent, and secondly that HER2 was not the sole driver of 
tamoxifen resistance in early breast cancer [4, 5]. 
The type I RTK family (HER1-4) form 10 homo- or heterodimers and are activated by a broad range of ligands 
leading to a complex inter-relationship between signaling kinases and downstream pathways [3]. There is 
evidence that HER4 does not promote breast cancer proliferation in vivo and is linked to good prognosis in 
breast cancer patients [4, 6]. In contrast breast tumors expressing HER1, HER2 or HER3 receptors exhibit 
increased proliferation in vivo and are associated with poor outcome [4].  
Establishing the impact of specific genes on cancer prognosis in the clinical setting is complicated by multiple 
factors including; the impact of multimodal therapy (surgery, radiotherapy, chemotherapy, endocrine therapy), 
the size and consistency of the patient cohort and the frequency of marker expression. These challenges are 
recognized and addressed by existing guidelines (REMARK) [7]. Several studies have demonstrated time 
dependency of both molecular and clinical prognostic features of breast cancer [8, 9]. Both the time dependency 
of the impact of type I RTKs and the inter-relationship between different receptors in the RTK family require 
consideration in any approach to the determination of the prognostic or predictive impact of these markers in 
early breast cancer.  
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At the time of our 2005 study [4], results from the first clinical trials of AIs demonstrated the superiority of AIs 
regarding disease-free survival (DFS) when compared with tamoxifen for postmenopausal, estrogen receptor 
(ER) positive early breast cancer [10]. When linked to preclinical evidence that type I RTKs mediate resistance 
to tamoxifen, in part through intracellular signaling [11] and post-translational modification of ER [1, 12], this 
led to a hypothesis that clinical resistance to tamoxifen treatment mediated via HER1-3 expression and 
signaling could be circumvented/reversed by the clinical use of AIs [13]. Evidence from three trials (ATAC, 
BIG-1-98 and TEAM) [14-16] in which central HER2 testing was performed [17-19] provided support for an 
interaction between HER2 expression and response to AIs versus tamoxifen. However, the effect observed 
suggested that, contrary to earlier hypotheses, HER2 negative (HER2-ve) cancers derived maximal benefit from 
AIs whilst HER2 positive (HER2+ve) cancers appeared to exhibit a generalized endocrine resistance and might, 
in some trials, even perform worse on AIs rather than tamoxifen. However, none of the translational studies 
within these trials were, individually, statistically powered to provide high level evidence for the suggested 
interaction between endocrine therapy and HER2 which might impact clinical practice. 
This challenge led to the initiation, through the Translational sub-group of the Aromatase Inhibitor Overview 
Group (Trans-AIOG) of the current meta-analysis of data from 3 randomised trials (ATAC, BIG-1-98 and 
TEAM). No HER1/3 data was available from two studies limiting the current analysis to testing the interaction 
between HER2 and AI versus tamoxifen treatment in the first 2-3 years of treatment using a two-sided statistical 
test. This interval was chosen as most likely to impact clinical decisions relating to the initiation of early AI 
therapy versus the use of a switching strategy (TamAI). In addition, this analysis plan may account for time 
dependent effects of HER2 observed in multiple studies and allows inclusion of patients from both switching 
and continuous treatment arms maximizing statistical power. We report the results of this prospectively planned 
analysis designed according to the guidelines produced by Simon et al [20], to produce level IB evidence 
relating to the proposed treatment by marker effect. 
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Materials and Methods 
A predefined statistical analysis plan to determine by individual patient data (IPD) meta-analysis the use of 
HER2 as a biomarker for selection of upfront AIs compared to tamoxifen in the first 2-3 years of treatment in 
postmenopausal early breast cancer patients was developed and approved by the Trans-AIOG core investigators 
(JMSB, DR, GV, MMR, IS, CLB, IA; see supplementary data). The hypothesis to be tested was that HER2 is a 
predictive biomarker for AI benefit in HER2–ve patients during the first 2-3 years of endocrine therapy, i.e. that 
benefit from AIs over tamoxifen in that time period is not seen in patients with HER2+ve disease but is 
confined to patients with HER2-ve disease. 
The primary outcome was defined as distant recurrence-free interval (DRFI) up until the (pre-planned) 2-3 year 
treatment switch time (for trials with a switching element). DRFI was measured in days for all patients from 
randomisation date until earliest documentation of distant recurrence, or was censored at the visit date when 
treatment switch occurred, or would have occurred if assigned to do so (around 2-3 years depending on trial 
protocols), or at last follow-up or death without distant recurrence, whichever was earliest. A secondary 
outcome analysis was invasive disease-free survival (IDFS) up until the 2-3 year treatment switch time to be 
measured in days for all patients from randomisation date until earliest documentation of recurrent disease to 
include any invasive ipsilateral recurrence, invasive contralateral disease, loco-regional or distant recurrence, 
any second primary (non-breast) malignancy, or death from any cause.  Patients alive and in follow-up without 
evidence of disease were censored at the visit date when treatment switch (around 2-3 years) occurred, or would 
have occurred or last follow-up, whichever was earlier. 
Data collection and audit 
Following approval of the SAP by each translation science group the IPD analysis used data from patients 
randomised from three trials TEAM [14], ATAC [15] and BIG 1-98 [16]. All biomarker data included in this 
meta-analysis have been previously published [17-19]. Information was sought for every eligible patient 
included in the sub-study including randomisation date, age at enrollment, histological grade, stage, nodal 
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information, tumour size, adjuvant and neoadjuvant treatment, disease recurrence (including dates of first local, 
regional, distant, new primary disease), follow-up status and time, survival status and cause of death.  
Sample Size 
Using sample size calculations methods proposed by Schmoor [21], with a two-sided alpha of 0.05 and 
assuming an interaction hazard ratio (HR) of 2.44, 5.8% event rate, and HER2-positive prevalence of 10%, a 
sample size of 12448 patients would give greater than 90% power to detect a treatment–biomarker interaction 
within the 2-3 year treatment period.  The sample size was calculated using the ‘powerEpiInt2’ function in the 
‘powerSurvEpi’ [22] package in R (R Foundation for Statistical Computing, Vienna, Austria). 
HER2/ER/PgR positivity 
HER2 status was determined centrally and recorded as either positive or negative in each study according to 
published protocols [17-19] and complied with the ASCO-CAP guidelines updated in 2013 [23].  
All three participating trials assessed estrogen receptor (ER) and progesterone receptor (PgR) status centrally 
using different staining methodologies for each trial [17, 18, 24, 25]. For all eligible patients, ER positivity was 
defined as ≥1%, similarly PgR-positivity was defined ≥1% according to ASCO-CAP guidelines [26].  
Statistical methods 
Individual patient-level data (IPD) were collected centrally in Birmingham, UK. The statistical analysis was 
performed on an intention-to-treat basis within each of the three trials. Patients were excluded from the analysis 
if tumors were not ER-positive on central testing (<1% immunoreactive cells or ER not determined) or if HER2 
status was not centrally determined. An IPD meta-analysis of HER2 as a predictive biomarker for response to 
AI versus tamoxifen treatment was conducted. Log hazard ratios (HRs) were calculated (separately for HER2-
ve and HER2+ve) for each trial taking into account other important prognostic factors (age at enrollment, grade, 
size, nodal status) and then combined using random-effect inverse variance meta-analysis to give an overall 
treatment-by-biomarker effect estimate [27]. The interaction term between HER2 and the treatment assignment 
was calculated in each trial separately, and then pooled together across the three trials using a random-effects 
meta-analysis. This analysis was performed for both the primary and secondary endpoints. 
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Results 
In total 23,669 women were randomized to the TEAM (9779), ATAC (5880) and BIG-1-98 (8010) clinical 
trials (Supplementary Table 1). Collectively 13,336 tissue samples were received at the core pathology 
laboratories, and 12,671 successfully stained for the biomarkers ER, PgR and HER2. Translational data from all 
3 trials were collected centrally and following central checking 542 cases were excluded from the analysis 
because they were ER negative or unknown or had missing HER2 status. In total 12,129 cases (97.4% of the 
planned sample size) were available for this analysis (Supplementary Table 1). Overall 1092 (9%) patients had 
HER2 positive disease, ranging from 6.3% to 12.3% across the three trials (Supplementary Table 2).  
Differences between the trial cohorts with respect to clinicopathological variables reflect the recruitment 
strategies for each trial. Within each trial the translational cohorts have been previously shown to represent the 
main populations [17, 18, 24, 25] (Supplementary Table 2). Overall, 473/12129 patients (3.9%) experienced a 
distant recurrence within the 2-3 year period defined for the analysis, and 892/12129 (7.4%) patients 
experienced an IDFS event (Supplementary Table 3). 
Treatment-by-HER2 interaction 
The prospectively-planned IPD meta-analysis across 3 phase III trials demonstrated a significant treatment (AI 
vs. tamoxifen) by marker (HER2 status) interaction in both univariate (interaction HR=1.76, 95%CI 1.14-2.71; 
p<0.05) and multivariate analysis (interaction HR=1.61, 95%CI 1.01-2.57; p<0.05). These pooled results for the 
unadjusted and adjusted HER2 and treatment interactions are similar, with both HRs greater than 1 (Figure 
1A,1B) confirming a statistically-significant difference in the treatment effect (AI versus tamoxifen) between 
HER2 positive and HER2 negative cancers. Whilst there is evidence of heterogeneity for this effect between 
trials (I squared of approximately 60%) this effect does not reach statistical significance.  
Overall, in line with the treatment-by-marker interaction result, the HER2-ve group gained greater benefit from 
AI versus tamoxifen in both the unadjusted analyses (Figure 2A) and adjusted analyses for clinicopathological 
variables (adjusted HR=0.70, 95%CI 0.56-0.87) than the HER2+ve group (HR=1.13, 95%CI 0.75-1.71) (Figure 
8 
 
2B). For HER2-ve cases similar HRs were observed in all three trials with no significant heterogeneity 
(adjusted analyses, I squared=0%, p=0.587). However, significant heterogeneity was observed between trials 
for the HER2+ve subgroup (I-squared=70.8% p<0.05; Figure 2B). The small number of HER2+ve cases 
(1092/12129 across 3 trials) and distant recurrences (111 for HER2+ve cancers across all trials) may in part 
explain the heterogeneity between trials for this effect. Overall for the 12,129 patients included in this study 
with centrally confirmed ER and HER2 status, treatment with AIs resulted in a 22% reduction in risk of distant 
recurrence when compared to tamoxifen (HR=0.78, 95%CI 0.64-0.94) when results were pooled across all cases 
(HER2 +ve and HER2-ve). 
Trial by trial subgroups 
Individual analyses within each trial cohort confirmed a significant treatment-by-HER2 effect within the TEAM 
trial population, in both unadjusted (HR=2.66; 95%CI 1.47-4.82, p<0.001; Supplementary Table 4) and 
adjusted (HR=2.75, 95%CI 1.38-5.48, p=0.004; Supplementary Table 5) analyses. However, within the ATAC 
trial the treatment-by-marker effect did not reach statistical significance in either the unadjusted (HR=1.87; 
95%CI 0.62-5.65; p>0.05; Supplementary Table 6) or adjusted analyses (HR=1.44, 95%CI 0.46-4.96; p>0.05; 
Supplementary Table 7). Finally, the BIG-1-98 trial showed no evidence for a treatment-by-marker interaction 
in either unadjusted (HR=0.86, 95%CI 0.40-1.85; Supplementary Table 8) or adjusted analyses (HR=0.87, 
95%CI 0.40-1.87; Supplementary Table 9). 
Invasive Disease-free Survival 
A secondary pre-planned analysis of IDFS showed similar results in both adjusted and unadjusted analyses with 
a statistically significant (p<0.05) treatment-by-HER2 interaction (Figure 3A,3B). However, there was 
statistically significant heterogeneity in the treatment-by-marker effect between different trials (p<0.05, Figure 
3A,3B). Results are again similar for the unadjusted and adjusted treatment effects in the two HER2 subgroups 
(Figure 3). The treatment effects for the HER2-ve group are statistically significant in favour of AI treatment 
(HR=0.77, 95%CI. 0.67-0.89) with minimal heterogeneity between the 3 trial cohorts (Figure 3B). Whilst the 
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pooled treatment effect for the HER2+ve group is greater than 1 (favouring tamoxifen) the 95%CI crosses 1 
(Figure 3A, 3B) and there is significant heterogeneity between trials (I squared>80%, p<0.05).  
 
Discussion 
In this preplanned individual patient-level data meta-analysis across 3 pivotal randomized trials (ATAC, BIG-1-
98 and TEAM) using data from 12,129 postmenopausal, ER+ve early breast cancer patients with centrally 
determined ER and HER2 status, we demonstrated a significant interaction between HER2 status and treatment 
with AIs versus tamoxifen in the 2-3 years of adjuvant endocrine therapy (prior to the clinically-relevant point 
of “switching” between tamoxifen and AIs) (interaction HR=1.61, 95%CI 1.01-2.57, p<0.05). Patients with 
HER2-ve cancers experienced improved outcomes (30% reduction in distant relapse risk) when treated with an 
AI whilst patients with HER+ve cancers fared no better, or slightly worse during AI treatment in this period. 
This prospectively planned and statistically powered analysis achieved 97.4% of the prospectively planned 
sample size, was compliant with both BRISQ and REMARK guidelines [7, 28] and satisfies the required criteria 
for level 1B evidence according to Simon et al [20]. Whilst heterogeneity was observed in the HER2 positive 
subgroup, which represents under 10% of the entire population, this heterogeneity did not reach statistical 
significance within the primary endpoint population. In all aspects this analysis satisfies the current standards 
for a practice changing validation of a predictive biomarker in early breast cancer [20].  
However, as with all such studies, results must be applied in the context of existing breast cancer treatment 
options available to patients. Critically, for the majority of HER2+ve cases Herceptin/trastuzumab™ treatment 
was not available in the absence of chemotherapy at the time of conduct of the 3 trials used in this analysis. 
Therefore, for HER2 positive breast cancers the potential impact of HER2-directed therapies remains unknown, 
this alone precludes recommendations to change practice. Furthermore, whilst this study might be interpreted to 
suggest that patients with HER2+ve cancers derive no benefit in terms of freedom from distant recurrence from 
upfront AI (versus tamoxifen) treatment (within the first 2-3 years), we recognize that this study includes 
heterogeneous results from different studies which preclude recommendations to change treatment. Importantly, 
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the small number of HER2+ve cancers and recurrences in even this large analysis may explain the large degree 
of heterogeneity in the HER2+ve subgroups across all 3 trials. Rates of HER2 positivity varied between trials 
(6.3%, 10.6% and 12.3% in BIG-1-98, ATAC and TEAM respectively) despite all 3 trials using ASCO-CAP 
guidelines for HER2 testing [29]. Almost 50% of the HER2+ve cancers and over 50% of distant recurrences in 
the HER2 positive subgroup were from a single study, the TEAM trial, which was the only study to use 
exemestane, an irreversible, non-competitive AI. Furthermore, these results only apply to treatment and events 
occurring during the first 2-3 years of treatment (pre-switching) and do not provide information on longer term 
patient outcome. These results contrast with the recent meta-analysis from the EBCTCG where no interaction 
between HER2 and treatment was observed. The EBCTCG analyses, however, combined trials with switching 
strategies and those comparing 5 years of AI versus tamoxifen [30], and used locally- rather than centrally-
determined ER and HER2 results testing. Further, within the overview over 70% of cases had “unknown” 
HER2 status reflecting the lack of data in this field. In addition, emerging evidence of activity for both 
EGFr/HER2 as candidate predictive biomarkers, although currently restricted to a single study [17], suggest 
additional research is required using a broader approach to determining the effects of type I RTK signaling. 
This meta-analysis provides further evidence for differential benefit from upfront AI versus tamoxifen treatment 
between HER2+ve and HER2-ve ER positive postmenopausal early breast cancer patients. This study supports 
the positive impact of upfront AI in HER2-ve cancers. It raises the challenging possibility that treatment of 
HER2+ve luminal breast cancers with AI may, at best, provide no additional benefit over tamoxifen, and at 
worst be detrimental. However, we cannot at this time provide irrefutable evidence for such a detrimental effect 
especially in the context of HER2-targeted therapies. Therefore, on the basis of this study it is not appropriate to 
suggest excluding HER2 positive breast cancers from early treatment with aromatase inhibitors. Nor do we 
propose changes to current adjuvant endocrine therapy guidelines on the basis of HER2 status. The observed 
heterogeneity between trials, coupled with minimal treatment using HER2 directed therapies in this group 
precludes recommendations to change patient management at this time. However, the observed effect, coupled 
with previous data from the TEAM study [17] (combining EGFr/HER2/HER3) provides strong support for 
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further research in this field, aiming to further knowledge on optimal endocrine therapy for subgroups of ER+ve 
postmenopausal breast cancer patients. 
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Figure Legends 
Figure 1:  
Forest plots for DFRI biomarker and treatment interaction. 
Panel A = unadjusted/univariate. Panel B = adjusted/multivariate analysis.  
Figure 2:  
Treatment (AI versus Tam) effect by marker (HER2) by trial and combined.  
Panel A = unadjusted/univariate analysis. Panel B = adjusted/multivariate analysis.  
Figure 3:  
Treatment (AI versus Tam) effect by marker (HER2) by trial and combined for DFS (secondary endpoint). 
Panel A = unadjusted/univariate analysis. Panel B = adjusted/multivariate analysis.  
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